Tests Port Delivery System with ranibizumab refilled every 36 weeks in neovascular AMD
Tests a refillable eye implant with ranibizumab in adults with wet macular degeneration.
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Lyon, Montauban, Nantes, Paris, Poitiers, and Strasbourg Cedex, FranceSee the 6 sitesAlso in 12 other countries, 60 sites
- Trial code
- Registry title
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 250 people, planned
- Started
- 27 Nov 2025
- Expected to end
- 15 Nov 2028
- Type of study
- Interventional
- Treatments tested
- Susvimo PDS Implant
- Ranibizumab
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 or older with neovascular age-related macular degeneration (nAMD) who have already responded to anti-VEGF eye injections. It tests a port implant refilled every 36 weeks.
- Age
- 50 years or older
- Sex
- All sexes can join.
- Disease stage
- nAMD first diagnosed within 24 months before screening, with a good response to earlier anti-VEGF injections. Vision in the study eye of 34 letters or better on the ETDRS chart (BCVA).
- Earlier treatment
- At least 3 anti-VEGF injections into the eye for nAMD within 6 months before screening. Cannot have had brolucizumab, gene therapy for nAMD, an eye implant, or earlier experimental nAMD treatments.
Main reasons for not taking part
- Earlier eye surgery for AMD, a corticosteroid injection in the eye, or an eye implant
- Active eye inflammation, uveitis, or other eye infections
- Bleeding under the retina at the centre of the fovea, or scarring or atrophy under the fovea
- Stroke, heart attack, or new atrial fibrillation within the last 3 months, or uncontrolled blood pressure
- Active cancer within 12 months, with a few exceptions named in the record
The registry criteria, word for word
Show all 51 criteriaShow less
Who can take part
- Initial diagnosis of nAMD within 24 months prior to screening
- Previous treatment with at least 3 anti-vascular endothelial growth factor (VEGF) IVT injections for nAMD per standard of care within 6 months prior to screening
- Demonstrated response to prior anti-VEGF IVT treatment since diagnosis
- Availability of historical VA data obtained at or after nAMD diagnosis and prior to the first anti-VEGF treatment for nAMD
- Availability of historical OCT image data obtained at or after nAMD diagnosis and prior to the first anti-VEGF treatment for nAMD
- BCVA of 34 letters or better using ETDRS chart at a starting distance of 4 meters at screening and enrollment visits
Who cannot take part
- Prior Ocular Treatment; Study Eye:
- Previous treatment with corticosteroid intravitreal injection
- Previous intraocular device implantation
- Prior participation in a clinical trial involving any experimental therapies for nAMD
- Prior treatment with brolucizumab or gene therapy for nAMD
- Concurrent Ocular Conditions:; Study Eye:
- Any concurrent intraocular condition that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results
- Retinal tears or peripheral retinal breaks on depressed fundus exam that are untreated or treated within 3 months prior to the enrollment visit
- Concurrent Systemic Conditions:
- History of stroke within the last 3 months prior to informed consent
- Atrial fibrillation diagnosed or worsened within the last 3 months prior to informed consent
- History of myocardial infarction (MI) within the last 3 months prior to informed consent
- Chronic use of oral corticosteroids
- History of vitreous hemorrhage
- History of rhegmatogenous retinal detachment
- History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
- History of corneal transplant; Either Eye:
- History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the ranibizumab injections, study-related procedure preparations (including fluorescein), dilating drops, or any of the anesthetic and antimicrobial preparations used by a participant during the study
- Subretinal hemorrhage that involves the center of the fovea
- Uncontrolled ocular hypertension or glaucoma
- History or presence of severe posterior blepharitis, recurrent chalazia or hordeolum, severe dry eye syndrome, or severe allergic conjunctivitis
- Active or history of facial nerve palsy/paresis; Fellow (Non-study) Eye:
- Any active or history of uveitis
- Active or history of keratitis, scleritis, endophthalmitis, or chronic blepharitis
- Active or history of floppy eyelid syndrome
- Active thyroid eye disease
- Active or history of autoimmune diseases
- Confirmed active systemic infection
- Active cancer within 12 months of enrollment except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer
- History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the implant and that might affect interpretation of the results of the study
- History of vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD)
- Macular Neovascularization/Choroidal Neovascularization (MNV/CNV) Lesion Characteristics:; Study Eye:
- Subfoveal fibrosis or subfoveal atrophy; Either Eye:
- CNV due to other causes, such as ocular histoplasmosis, trauma, central serous chorioretinopathy, or pathologic myopia
- CNV masquerading lesions
- Subfoveal and/or juxtafoveal retinal pigment epithelial tear
- Active intraocular inflammation
- Aphakia or absence of the posterior capsule
- Trichiasis
- Corneal neuropathy
- Lagophthalmos or incomplete blink
- Non-functioning non-study eye defined as either: BCVA of hand motion or worse OR no physical presence of non-study eye (i.e., monocular); Either Eye:
- Suspected or active ocular or periocular infectious conjunctivitis or endophthalmitis
- Uncontrolled blood pressure
- Use of any systemic anti-VEGF agents
This trial is currently available in France.
Also in 12 other countries, 60 sites
- Hospital Edouard HerriotLyon, FranceTaking people
- Clinique Honoré CaveMontauban, FranceTaking people
- Institut Ophtalmologique De l Ouest Jules VerneNantes, FranceTaking people
- Centre Hospitalier National d'Ophtalmologie des Quize-VingtsParis, FranceTaking people
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranceTaking people
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex, FranceTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
The group in the trial
- Port Delivery System (PDS)Treatment being tested
Participants will have the PDS implant (pre-filled with 100 mg/mL of ranibizumab) \[approximately 2-milligrams (mg) dose\] surgically inserted in the study eye on Day 1. Participants who meet the disease activity criteria (DAC) at Week 24 or receive supplemental treatment with intravitreal (IVT) injections of ranibizumab prior to Week 24 will receive implant refill exchanges every 24 weeks (Q24W). Participants who do not meet the DAC at Week 24 and have not received supplemental treatment will receive PDS refill exchanges Q36W.
Treatment: Susvimo PDS Implant and Ranibizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase IIIb, Multicenter, Single-arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration
- Plain-language title
- Tests Port Delivery System with ranibizumab refilled every 36 weeks in neovascular AMDGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 November 2026